NXGLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as NXGLW
NEXGEL, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026
$5.80+0.21 (+3.76%)
Close on Oct 19, 2026
- Market cap
- $52.28M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
39.5%+82.7 pts over 5 years
Operating margin
-29.3%+306.0 pts over 5 years
Net margin
-26.3%+309.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +31.5% | +77.3% | +76.1% | – | |
| Gross profit | +64.1% | +160.2% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -1004.0% | -58.7% | |
| Return on assets | – | -109.2% | -28.0% | |
| Current ratio | – | 0.27 | 1.47 | |
| Debt to equity | – | 3.61 | 0.11 | |
| Net debt to EBITDA | – | -0.10× | -0.06× | |
| Interest coverage | – | – | -98.6× | |
| Inventory turnover | – | 5.6× | 3.6× | |
| Capex to revenue | – | 46.3% | 0.6% | |
| Diluted shares | – | 2M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nexgel generated $14.16M from operations and spent $1.57M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$14.16M
Used
$1.57M
Capital expenditure$1.57M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-26.3%
×Asset turnover1.07×
×Equity multiplier2.10×
=Return on equity, FY2025-58.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -26.3% | 1.07× | 2.10× | -58.7% |
| FY2024 | -37.8% | 0.83× | 2.00× | -62.8% |
| FY2023 | -77.2% | 0.40× | 1.65× | -51.2% |
| FY2022 | -231.7% | 0.15× | 1.39× | -48.1% |
| FY2021 | -277.9% | 0.16× | 1.58× | -70.9% |
| FY2020 | -335.9% | 0.33× | 9.20× | -1004.0% |
| FY2019 | -268.2% | 0.55× | 3.98× | -581.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$3.00M
- Cash generatingOperating cash flow above zero-$1.31M
- Return on assets improvedROA up on the prior year-33.0% → -27.3%
- Earnings backed by cashOperating cash flow above net income-$1.31M vs -$3.00M
- Less leverageLong-term debt to assets fell5.4% → 4.7%
- Better liquidityCurrent ratio rose2.07 → 1.47
- No dilutionShare count did not rise7M → 8M
- Gross margin improvedGross margin up on the prior year31.63% → 39.48%
- More efficientAsset turnover rose0.87 → 1.04